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Abstract
Genetic and genomic studies highlight the substantial complexity and heterogeneity of human cancers and emphasize the
general lack of therapeutics that can match this complexity. With the goal of expanding opportunities for drug discovery,
we describe an approach that makes use of a phenotype-based screen combined with the use of multiple cancer cell lines.
In particular, we have used the NCI-60 cancer cell line panel that includes drug sensitivity measures for over 40,000
compounds assayed on 59 independent cells lines. Targets are cancer-relevant phenotypes represented as gene expression
signatures that are used to identify cells within the NCI-60 panel reflecting the signature phenotype and then connect to
compounds that are selectively active against those cells. As a proof-of-concept, we show that this strategy effectively
identifies compounds with selectivity to the RAS or PI3K pathways. We have then extended this strategy to identify
compounds that have activity towards cells exhibiting the basal phenotype of breast cancer, a clinically-important breast
cancer characterized as ER-, PR-, and Her2- that lacks viable therapeutic options. One of these compounds, Simvastatin, has
previously been shown to inhibit breast cancer cell growth in vitro and importantly, has been associated with a reduction in
ER-, PR- breast cancer in a clinical study. We suggest that this approach provides a novel strategy towards identification of
therapeutic agents based on clinically relevant phenotypes that can augment the conventional strategies of target-based
screens.
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Introduction
Numerous advances have been achieved in the development,
selection and application of chemotherapeutic agents, sometimes
with remarkable clinical successes, as in the case of treatment of
leukemias and lymphomas with combined cytotoxic reagents,
testicular cancer with platinum, and estrogen receptor positive
breast cancers with Tamoxifen [1]. Recent work has also
demonstrated the value in targeting the specific molecular lesions
responsible for the development and maintenance of the
malignant phenotype. This is perhaps best illustrated by the
example of chronic myelogenous leukemia (CML), a disease
driven by the BCR-ABL oncoprotein common to virtually all
patients and sensitive to Gleevec, an inhibitor of BCR-ABL [2].
Nevertheless, in the vast majority of cancers, targeted therapies are
active in only a small fraction of patients [3]. An example is
Herceptin, which targets breast cancers with Her2 overexpression,
representing only 18–20% of all cases [4].
Conventional approaches for drug discovery have either used
biochemical, target-based assays or cell-based assays that focus on
a particular activity [5,6,7]. This continues to be an important
strategy that benefits from the use of genomic studies to identify
critical targets [8]. But, the same genomic technology can also be
used to broaden the potential target and develop new screening
methods that are grounded in relevant phenotypes. An alternative
strategy might focus on a cancer-relevant phenotype rather than a
specific molecular target. In fact, the past several years have seen
great advances in the use of DNA microarray data to develop
expression signatures that coincide with important cancer
phenotypes including tumor aggressiveness, metastasis, and
resistance to therapy [9,10,11,12,13,14]. The challenge is to
develop an assay system that both reflects the phenotype of interest
but is also high-throughput to afford an ability to utilize large
compound libraries for the identification of lead compound. We
have applied a strategy based on phenotype signature to the NCI-
60 drug screening dataset, taking advantage of the potential to link
relevant expression signatures with action of a large number of
potential cancer therapeutics. Importantly, of the 40,000 or more
compounds that have been used for screening of the NCI-60
panel, a substantial number of these have been used in clinical
studies. As such, a strategy that could identify therapeutics with
cancer activity from amongst this group of clinically-approved
agents, has the potential to rapidly move new therapeutics into
clinical practice.
Materials and Methods
Cell culture and drug application
Methods to culture and test the drug sensitivity of 19 breast
cancer cell lines are described previously [15]. We performed 12
independent in vitro cell proliferation assays for Simvastatin and
Peplomycin, and 8 for Tamoxifen, and then calculated GI50
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software. Averages of GI50 values were used for further statistical
analysis. Simvastatin (S3449) and Tamoxifen (T5648) were
purchased from LKT Laboratories and Sigma, respectively.
Peplomycin was provided courtesy of Nippon Kayaku. We
examined the relationship between drug response and phenotype
in experiments using the non-parametric Mann Whitney U-test
and linear regression using GraphPad’s Prism software.
Statistical analyses of microarray data
Analysis of expression data was described in detail previously
[16,17]. A metagene represents a group of genes that together
exhibit a consistent pattern of expression in relation to an
observable phenotype. Each signature summarizes its constituent
genes as a single expression profile, and is here derived as the first
principal component of that set of genes (the factor corresponding
to the largest singular value) as determined by a singular value
decomposition. Given a training set of expression vectors (of values
across metagenes) representing two biological states, a binary
probit regression model is estimated using Bayesian methods.
Applied to the NCI-60 expression data, this leads to evaluations of
predictive probabilities of each of the two states for each cell line.
When predicting the pathway activation or the evidence of the
phenotype of cancer cell lines, gene selection and identification is
based on the training data, and then metagene values are
computed using the principal components of the training data
and additional cell line or tumor expression data. Bayesian fitting
of binary probit regression models to the training data then
permits an assessment of the relevance of the metagene signatures
in within-sample classification, and estimation and uncertainty
assessments for the binary regression weights mapping metagenes
to probabilities of relative pathway status. Predictions of the
relative status of the NCI-60 cell lines are then evaluated,
producing estimated relative probabilities of the pathway activa-
tion or the evidence of the phenotype across the NCI-60 cell lines.
Signatures for cancer cell phenotypes
To generate a signature that distinguishes basal or luminal subtype
of breast cancer, we used a gene expression dataset E-TABM-157
[18] (ArrayExpress; http://www.ebi.ac.uk/arrayexpress/) that in-
cluded 26 samples with basal and 25 with luminal subtypes. To
validate the ‘‘basal-luminal’’ signature from cultured cell lines, we
used three independent datasets for human in vivo breast cancer
(GEO; http://www.ncbi.nlm.nih.gov/geo; GSE1456, GSE1561 and
GSE3744) [19,20,21]. Gene expression signatures for RAS and PI3K
used in this study were generated by adenoviral overexpression of a
constitutive active mutant of H-RAS (H-RAS V12) and wild type
p110a subunit of PI3K, respectively, in primary cultured human
mammary epithelial cells [14,17]. The conditions to generate the
signatures are dependent upon empirically determined multiple
parameters, particularly the number of genes to prioritize and the
number of metagenes. These detailed conditions are described in
Table S1. We also analyzed the influences of these factors to the
correlations between RAS signature and the sensitivity to Hypothe-
mycin, and between PI3K signature and the sensitivity to LY294002
(Figure S2).
Compound sensitivity data of NCI-60 cell lines
Drug response data for NCI-60 cell lines were available from
http://www.dtp.nci.nih.gov/. GI50 (drug concentration for 50%
growth inhibitory effects on cells) values were available for 44,653
compounds (Release September 2005). We found the data
includes many compounds that were assayed on a limited number
of cell lines or whose effects did not suffice for calculating GI50s.
To improve the validity of the data, we filtered the compounds
that were assayed on fewer than 30 samples and also the
compounds whose efficacy could not be measured at the assayed
concentrations in over 50% of the assayed samples. This yielded
21,603 compounds, among which 6,638 have chemical names (or
equivalents).
Conversion of gene expression signature to drug
response
We used the gene expression data of the NCI-60 on Affymetrix
U133A/B chips from GEO (GSE5720) [22] for the analyses in this
study. To select compounds, we calculate the Pearson correlation
between the predicted probability for the phenotype of interest
against the GI50 values of each of the compounds. To preserve the
structure of the distribution of the phenotype probabilities and
GI50 values, we calculated the p-values for the correlations by
permuting the labels for the phenotypes 1610
6 times and counting
the number of times we obtain the original correlation by chance.
We calculated the false discovery rate (FDR) using the method of
Benjamini & Hochberg to determine a cut-off value for the
selection of compounds [23]. GI50 values of correlated com-
pounds were centered and normalized by Gene Cluster 3.0
(http://bonsai.ims.u-tokyo.ac.jp/,mdehoon/software/cluster/),
then visualized by Matlab, R with Bioconductor software (http://
www.bioconductor.org/) or JavaTreeView (http://sourceforge.
net/projects/jtreeview/).
Mouse xenograft model
Athymic nude mice (nu/nu) were obtained from Charles River
Laboratories or the Cancer Center Isolation Facility at Duke
University and maintained in a sterile environment according to
guidelines established by the US Department of Agriculture and
the American Association for Accreditation of Laboratory Animal
Care. This project was approved by the Institutional Animal Care
and Utilization Committee of Duke University. Athymic mice
were inoculated with in vitro propagated MDA-MB-231 cells (10
6
in 100 ml) subcutaneously injected into each flank. Twelve days
after tumor inoculation, we initiated treatment. Day 0 marks the
first day of treatment. For Simvastatin treatment, tumors were
randomly divided into two groups of 10 mice; control and drug
treatment. Simvastatin tablets (Zocor, Merck) were mixed with
food and pressed into pellets by Harlan Tekland at 1 g
Simvastatin/1 kg diet to deliver a dose of 200 mg/kg mouse/
day, assuming a 25 g mouse consuming 5 g chow per day. The
dosage was reported to be equivalent to the maximal dosage for
humans and was well tolerated by mice in a previous study [24].
Untreated animals received pellets without Simvastatin. Tumors
were measured every 3 or 4 days with calipers in three dimensions.
The following formula was used to calculate tumor volume:
Tumor volume=WxLxHx0.5236 (W, the shortest dimension; L,
the longest dimension; H, the height). The growth curves are
plotted as the mean tumor volume +/2 s.e.m. Average tumor size
at day 0 was same between treated and control mice (Simvastatin
control; 36.23 +/2 8.359 mm




Concept of an expression signature-based drug screen
To expand opportunities for cancer drug development, we have
explored the concept of using cancer-relevant gene expression
signatures as the basis for a screen, rather than the conventional
approach of utilizing well defined biochemical targets. The logic in
the use of signatures is the ability to greatly expand the number of
Drug Discovery by Genomics
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activity, recognizing the fact that a target-based approach is
limited by available targets that are amenable to conventional
drug screens. Pathways such as MYC and SRC represent one
opportunity but the concept can go well beyond to include other,
less defined, cancer relevant phenotypes that can be represented as
expression signatures including poor prognosis, metastasis, or
general resistance to therapies.
To explore this concept of using signatures as the basis for a
drug screening strategy, we have made use of several examples
that represent potential drug targets and coupled these with data
from the NCI-60 cancer cell line drug screening panel. Over
40,000 compounds have been assayed using the NCI-60 panel,
thus representing a series of cell-based drug screens done in
parallel [7]. Our approach uses signatures to identify cell lines
within the NCI-60 panel that strongly exhibit the signature, and
then identify compounds from the NCI-60 dataset that are active
against those specific cell lines (Figure 1). An important aspect of
the approach is the identification of multiple cell lines that exhibit
a given signature and that share sensitivity to a compound or
compounds.
A screen for pathway-specific drugs
In order to illustrate the concept in the context of cell signaling
pathways that are considered important cancer therapeutic
targets, we have focused on two well studied pathways: RAS
and PI3K. In each case, activation of these proteins and pathways
is known to contribute to the development of an array of cancers
[25,26,27]. Since each has been the subject of extensive drug
development, there are many compounds identified that target
components of the pathways, including compounds assayed in the
NCI-60 drug screen. This then provides an opportunity to validate
the concept of a signature based screen by determining if the
identification of NCI-60 cell lines that exhibit a RAS or PI3K
signature reveals compounds that are active against components of
the respective pathways.
We made use of previously developed expression signatures that
reflect the activity of RAS and PI3K to then profile the activity of
the pathways within the NCI-60 panel [14,17] (Figure 2A). One
point evident in this analysis is the distinction in cell lines
exhibiting activity of the two pathway signatures. These results
were then used to sort the NCI-60 cell lines based on the
predictions of RAS or PI3K activity to then identify compounds
that are most active against these cell lines. This result is shown in
Figure 2B as a heatmap displaying activity of the compounds,
sorting the cells by pathway prediction and the compounds by
relative activity for a given cell line. We identified compounds as
significant based on a multiple hypothesis corrected FDR (false
discovery rate),0.05. Using sequence information generated at
the Sanger Institute, we find that the predicted probabilities of
RAS pathway activation were indeed higher in cells with mutation
of BRAF or RAS (either N-, H- or K-RAS) than the wild type cells
for both loci with statistical significance [28] (RAS/BRAF wildtype
vs RAS or BRAF mutant; p=0.0001 by Mann Whitney test),
further validating specificity of RAS prediction in NCI-60 cells.
An examination of the compounds showing a significant
correlation with RAS activity revealed 3616 positively correlated
compounds and 606 compounds in negative correlation. Positive
Figure 1. Strategy of a gene expression signature-based drug screen. A gene expression signature that reflects a clinical/biological
phenotype is used to profile the NCI-60 panel to identify cells that exhibit the phenotype of interest. The predicted probability for the signature is
correlated against the sensitivity to over 40,000 (21,603 after filtering) compounds to identify compounds that appear to be effective in cells
exhibiting the phenotype.
doi:10.1371/journal.pone.0006772.g001
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target MAPK/ERK kinases (MEKs) [29] that are key downstream
effectors of the RAS pathway [25,26,27] (rank=331, R=0.4998
and FDR=0.002639). In principle, the identification of Hypothe-
mycin in relation to RAS pathway activation is analogous to
observations linking sensitivity of cells to the same MEK inhibitor
based on the presence of B-RAF mutations [30] (Figure 2C and
2D). Of course, there were many additional compounds that also
exhibited a positive correlation with the RAS activation pheno-
type, although their utility will require further experiments.
The parallel analysis using the PI3K pathway signature revealed
three compounds with a positive correlation and ten with a negative
correlation with FDR,0.05. The cells exhibiting the PI3K signature
were largely distinct from those exhibiting the RAS signature and
thus the drug profile linked to these two pathways was distinct.
Indeed, there are no overlapping compounds identified in both of
RAS and PI3K positive correlation. Although there were mutations
inPIK3CAorPTENintheNCI-60celllines,therewasnocorrelation
between these mutations and the sensitivity of LY294002, which can
specifically inhibit PI3K including activity resulting from gain of
function mutations [31]. Nevertheless, LY294002 is positively
correlated with this PI3K signature (Figure 2C and 2E). Taken
togetherthese observations suggest anability of the phenotype-based
screen to identify relevant compounds.
Figure 2. Identification of RAS or PI3K pathway-specific drugs. A. Gene expression signatures previously developed to predict RAS or PI3K
pathway activation were used to predict the status of the pathways in the NCI-60 panel. The predicted probability for each oncogene activity is
shown in a heatmap (lower panels; red=high and blue=low). Samples are sorted according to the RAS activity. B. A heatmap displaying the pattern
of compounds correlated with RAS or PI3K pathway status. GI50s of correlated compounds with FDR less than 0.05 are shown in a heatmap
(green=less sensitive and red=more sensitive) with the heatmap of predicted probabilities for RAS or PI3K activity (red=high and blue=low).
Samples and compounds are sorted according to the predicted probabilities for each oncogene activity and to the correlation coefficient,
respectively. RAS is positively correlated to 3616 compounds and negatively correlated to 606. For PI3K, three compounds have positive correlation
and ten have negative correlation. C. Pattern of correlation of all compounds with RAS (left) or PI3K (right) predicted probability. Correlation
coefficients in Pearson correlation are shown in a heatmap (green=less sensitive and red=more sensitive). Bars adjacent to the heatmap are used to
indicate the compounds with FDR less than 0.05. Hypothemycin, a MEK inhibitor, is a highly correlated compound to cells with high RAS probability
(rank=331, R=0.4998 and FDR=0.002639). LY294002 shows strong correlation to PI3K activity without evident statistical significance (rank=121,
R=0.3601 and FDR=0.1463). The correlation coefficient may suggest the ‘‘strength’’ of the correlation. D and E. Relation between oncogenic
pathway activity and pathway specific inhibitors in NCI-60 cell lines. GI50 values were plotted in the function of the predicted probalities. P value and
R
2 were calculated by linear regression analysis of GraphPad’s Prism. D. RAS pathway and hypothemycin. E. PI3K pathway and LY294002.
doi:10.1371/journal.pone.0006772.g002
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A second application of this approach is in a context of a
phenotype that lacks a defined molecular target. An example might
be a particular subgroup of cancer patients clearly at risk for disease
progression but lacking currently available therapeutics. Expression
data has been used to characterize human breast cancers into
subtypes that reflect the cell typeof origin,witha particular focus on
basal and luminal subtypes. Basal type breast cancers tend to be
estrogen receptor negative and exhibit a poor prognosis whereas the
luminal subtype tends to be estrogen receptor positive and have a
better prognosis [10]. Importantly, expression studies of cultured
breast cancer cell lines have shown that these cells retain their
subtype characteristics [18]. It seemed reasonable that the
identificationof drugs with specificity for the subtype could translate
into drugs effective for the patient. This could be particularly
important for the basal subtype given the general lack of effective
therapeutics for this group of breast cancer patients.
To identify compounds that potentially have activity specific for
the basal phenotype, we generated a signature to distinguish basal
or luminal phenotype using expression data derived from 26 basal
and 25 luminal subtype cell lines grown in in vitro tissue culture
(Figure 3A) [18]. As shown in Figure 3B–E, the signature derived
from the in vitro model has an ability to accurately predict the
status of human primary breast cancer samples from three
independent datasets, validating the predictive ability of the
signature. We then applied this ‘‘basal-luminal’’ signature to NCI-
60 expression microarray data to classify the cell lines according to
the degree of ‘‘basal-luminal’’ phenotype and identify compounds
that were most active against each cell type (Figure 4A). An
analysis of the significant associations revealed 5589 luminal
subtype correlated compounds while 568 compounds showed a
correlation to the basal subtype. Among the luminal phenotype
correlated drugs, Tamoxifen was identified as a high scoring
compound (Figure 4B) (rank=57, R=0.6140 and FDR=0.0000).
In human breast cancers, the luminal subtype is known to be
largely estrogen receptor positive and sensitive to estrogen
antagonists, including Tamoxifen [10]. Indeed, the predicted
probability of each NCI-60 cell line for luminal subtype was
strongly correlated with estrogen receptor 1 (ESR1) mRNA level
(average of RMA normalized expression of 205225_at,
211233_x_at and 211234_x_at on U133A chip; R
2=0.2551,
p,0.0001 by linear regression analysis).
Figure 3. Identification of breast cancer subtype specific compounds. A. Development of a gene expression signature to distinguish basal or
luminal cell type in breast cancers. Expression levels of selected genes are shown in a heatmap (high=red and low=blue). B. Validation of the ‘‘basal-
luminal’’ signature in three independent datasets of human primary breast cancers. The predicted probability for basal (blue) or luminal (red) are
shown in a heatmap with the labeling for the cell type classification by microarray (GSE1456), the immunoreactivity status for estrogen and
progesterone receptor (GSE1561) or the status for basal subtype by cytokeratin expression patterns (GSE3744). C, D and E. Prediction for basal and
luminal properties in in vivo tumor data sets. Predicted probabilities are plotted for the groups with the defined subtype and statistically evaluated
using Mann-Whitney U test. A bar indicates mean value for each group. The predicted probability for basal or luminal is shown with the labeling for
the cell type classification by microarray (C; GSE1456), the immunoreactivity status for estrogen and progesterone receptor (D; GSE1561) or the status
for basal subtype by cytokeratin expression patterns (E; GSE3744). Accuracy of the prediction was also shown. To evaluate the accuracy, 0.5 was used
as a cut-off value.
doi:10.1371/journal.pone.0006772.g003
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Tamoxifen and ESR1 expression level provides an additional
validation of the specificity of the methodology, a more pressing
question in the context of breast cancer therapy is the basal
phenotype since effective treatments for this group of patients are
limited. An analysis of the compounds selected on the basis of the
basal type phenotype revealed three clinically used drugs with high
scores. Drugsalready inclinicaluseareofhighestprioritysincetheir
characteristics, such as side effects and toxicity, have been well
described. These included Simvastatin and Lovastatin, HMG-CoA
reductase inhibitors, and Peplomycin, an inducer of DNA double-
strand breaks [32,33] (Figure 4B–F) (Simvastatin; rank=204,
R=0.5050 and FDR=0.006160, Lovastatin; rank=442,
R=0.3890 and FDR=0.02795 and Peplomycin; rank=329,
R=0.3910 and FDR=0.01478). In fact, previous studies have
indicated a role for lipophilic statins such as Simvastatin and
Lovastatin as inhibitors of farnesyl transferase activity and RAS/
RHO activity and to have the capacity to inhibit the growth of
breast cancer cells in vitro [34]. Based on these results, we then
further tested the activity of both Simvastatin and Peplomycin in
Figure 4. Relation between the ‘‘basal-luminal’’ phenotype activity and correlated drugs in NCI-60 cell lines. A. The predicted
probability of NCI-60 cells for ‘‘basal-luminal’’ subtype and the correlated compounds. The predicted probability of NCI-60 cells for the similarity to
basal (blue) or luminal (red) is shown in a heatmap and sorted according the similarity. Note that among 5 cell lines, which were characterized by the
previous study [18] and are included in NCI-60 cells, every cell line was classified accurately (basal subtype; blue arrowheads; BT549, MDA-MB-231 and
MDA-MB-435 and luminal subtype; red arrowheads; MCF7 and T47D). GI50 pattern for the compounds that correlated with the probability within 0.05
of FDR was shown in a heatmap (green=less sensitive and red=more sensitive). Luminal subtype correlated compounds include 5589, while 568
compounds showed correlation to basal subtype. B. Correlation pattern of all compounds with the predicted probability to ‘‘basal-luminal’’ signature.
Correlation coefficient in Pearson correlation is shown in a heatmap (green=less sensitive and red=more sensitive). Bars adjacent to the heatmap
are used to indicate FDR less than 0.05. Tamoxifen, an estrogen receptor inhibitor, is a highly correlated compound to cells with high luminal
probability (rank=57, R=0.6140 and FDR=0.0000). Among 568 compounds, which basal phenotype correlated within FDR of 0.05, 85 compounds
have chemical names. Through Pubmed search of all 85 compounds, Simvastatin, Lovastatin and Peplomycin are found to be currently under clinical
use (Simvastatin; rank=204, R=0.5050 and FDR=0.006160, Lovastatin; rank=442, R=0.3890 and FDR=0.02795 and Peplomycin; rank=329,
R=0.3910 and FDR=0.01478). Lovastatin is not shown in Figure 4B. C, D, E and F. Tamoxifen (C), Simvastatin (D), Lovastatin (E) and Peplomycin (F)
and the ‘‘basal-luminal’’ phenotype activity. GI50 values were plotted in the function of the predicted probabilities. P value and R
2 were calculated by
linear regression analysis of GraphPad’s Prism.
doi:10.1371/journal.pone.0006772.g004
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shown in Figure 5A, each drug showed activity to those cells that
exhibited the basal phenotype with a discrimination in relation to
the luminal phenotype. As expected, assay of Tamoxifen using this
same collection of cell lines yielded the inverse pattern, showing
activity in cells exhibiting the luminal phenotype but not the basal
(see also Figure S1 and Table S2 and S3).
Given the potential for Simvastatin as a basal subtype-specific
drug, we evaluated the capacity of this compound to inhibit tumor
growth in vivo, using a xenograft model with a basal subtype cell line
[35]. As shown in Figure 5B, Simvastatin very effectively blocked
tumor growth in this model, while the untreated controls grew
rapidly. Indeed, after 25 days of treatment the tumor volume was
879.0+/2280.7 mm
3 for untreated and 64.66+/226.68 mm
3 for
Simvastatin treated (p=0.0222 at Day 25 by unpaired t-test). Taken
together,theseresultssuggesta capacityforasignature-basedscreen
to identify candidate drugs for new cancer therapeutics.
Discussion
There have been major successes in the discovery and
development of new cancer therapeutics based on a knowledge
of the biology of the tumors, exemplified by Gleevec, Herceptin,
and Tamoxifen. However, it is also true that for most of cancers,
there remains a critical shortage of effective therapeutics that can
match the complexity of these diseases [1,2,4,36]. Many studies
now provide compelling evidence that various genomic profiling
approaches do have the capacity to dissect the complexity of
cancers with the potential to then match drugs with patients
[14,37,38,39,40]. With these advances, what becomes limiting is
the availability of a sufficient repertoire of drugs that could
eventually match the complexity of the cancers and thus a critical
need to substantially increase the pipeline of new therapeutics to
match these needs and opportunities. We believe the strategy
outlined here represents one opportunity to address this need.
Although conventional drug screens have yielded many effective
drugs, there are nevertheless two primary limitations that restrict
the opportunity to increase the development of new drugs and for
which a signature-based approach might be successful. First, many
potential targets are deemed unlikely to yield drugs (not
‘druggable’), based on the biochemical properties of the protein.
Oncogenic transcription factors such as MYC represent one
example. MYC is known to be deregulated in a large number of
human cancers yet there has been little successful development of
Figure 5. Experimental validation of compounds predicted to be active on breast cancer subtype. A. Specificity of drug sensitivity
measures in breast cancer cell lines. A panel of breast cancer cell lines was classified into basal or luminal subtype based on the microarray
classification (shown in Figure S1) and used for measures of sensitivity to Simvastatin (A), Peplomycin (B), and Tamoxifen (C). GI50 values were
calculated after cell proliferation assays of these breast cells and averaged GI50s were plotted with p value (also shown in Table S3). A non-parametric
Mann-Whitney U-test was used to evaluate the result statistically. B. Confirmation of in vivo effect of Simvastatin on a basal-type breast cancer cell
line. MDA-MB-231 cells were inoculated by subcutaneous injection into mice and then the mice were treated with Simvastatin for 12 days after
injections. Tumor size at day 0 was the same (see Materials and Methods in detail). Sizes of tumors were plotted as a function of days after the
initiation of treatment. The unpaired t-test was used for statistical evaluation and p value is shown with the plot. Asterisks indicate statistically
significant differences (p value: day 4; 0.0373, day 7; 0.0569, day 11; 0.0162, day 14; 0.0280, day 18; 0.0393, day 21; 0.0416).
doi:10.1371/journal.pone.0006772.g005
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reflecting MYC pathway activity could be employed to identify
drugs targeting other components of the MYC pathway that might
be more amenable to drug sensitivity. Indeed, various recent
studies suggest that pathway activation can be linked to sensitivity
to drugs targeting downstream components. As an example, cells
that harbor a RAF mutation exhibit sensitivity to MEK inhibitors
[30]. Also in our analysis, the identification of a MEK inhibitor
based on a screen with a RAS pathway signature provides a proof-
of-concept for this logic.
Second, the conventional approach that depends on the
identification and detailed biochemical understanding of the
nature of the target is a slow process and is limited by available
understanding of cancer mechanisms [5,6]. Once again, genomic
profiles provide further opportunities for identification of relevant
targets. For example, expression signatures that identify sub-classes
of cancers with aggressive characteristics or cancers resistant to
commonly used therapies represent therapeutic opportunities
[10,11,12,13,14]. In each instance, an ability to develop
therapeutics specific for these subtypes of cancer, whether breast
cancer, lymphoma, or others, would be a significant step forward
in expanding the arsenal of drugs that could be matched with
characteristics of the individual patient. Developing a phenotype
specific signature could be employed in a drug screen much like
the example of the basal specific breast cancer signature shown in
this work. In principle, this strategy could be expanded to virtually
any relevant cancer phenotype where there is a need for further
drug development, although the identification of the molecular
target may be needed in order to reduce or eliminate off-target
effects at further optimization step following to the initial drug
discovery phase.
The number of compounds identified by the expression
signatures varies considerably and may simply reflect the number
of similar compounds utilized in the NCI-60 screen; indeed, there
are a number of instances in which the NCI-60 compound library
contains many redundant chemicals with slightly modified residues
in their structures. Therefore it is not rare that the cellular
response to even a substantial number of the compounds show
similarity in the correlation with some molecular targets in the
previous study [43] or phenotypes such as the RAS activation and
luminal subtype in this study. On the other hand, only a very
limited number of compounds were correlated with the PI3K
signature. Nevertheless, the correlation of LY294002 with the
PI3K signature, but not with PIK3CA or PTEN mutational status,
suggests that the utilization of expression signatures can extend the
opportunities for identifying relevant candidate drugs and can
complement the previous NCI-60 drug screen methods relying on
mutational information [5,6,7,28,30].
We also note that other studies have provided related strategies
for drug discovery, again using expression signatures as the basis for
the screen. In one instance, genes that constitute a signature are
compared with genes that define response of cells to a variety of
drug treatments, thus connecting drug response with a phenotype.
In a second example, a signature reflecting the activity of a known
cancer target becomes the actual target for drug screening
[44,45,46,47]. This contrasts with the approach we describe that
makes use of the signature to identify cell lines that exhibit the
signature and thus the phenotype of interest that can then be scored
for drugs that selectively inhibit the proliferation of the cells. The
principal advantage of this approach is the ability to carry out a
screen where targets are not known. We do not suggest that one or
the other of these strategies is better but rather suggest that they
represent complementary approaches, along with conventional
target-based screens, to increase opportunities for drug discovery.
Many studies now point to the fact that most cancers are
extremely heterogeneous, likely reflecting a complex array of
disease mechanisms. Cancers such as breast cancer are not one
disease but rather a group of tens or even hundreds of diseases. As
such, the likelihood that one therapeutic or even one combination
of therapeutics will be effective in treating the myriad of breast
cancers is very low. Rather, the complexity of the disease must be
matched with an equally complex therapeutic arsenal if one hopes
to effectively treat the disease. Given this, an ability to substantially
increase the number of therapeutics moving through the
development process is critical and we suggest that the strategy
outlined could represent a key component of this process. We note
that a significant advantage of this approach is the potential to
identify new cancer therapeutics from a collection of drugs that
have already progressed through the initial stages of drug
development. As such, this greatly accelerates the process of
bringing new agents to clinical use. As with any example of a drug
screen, candidates identified by a signature-based screen must be
evaluated for their potential for further development. This can
involve a number of criteria typically used in the drug
development process but including other indications for potential
activity in a given context. As an example, the identification of
Simvastatin as a potential breast cancer therapeutic useful for
tumors of the basal subtype is interesting in light of previous work
that has shown a role for statins, including Simvastatin, in breast
cancer prevention [48]. Even more relevant with respect to the
potential specificity for breast cancer with a basal phenotype is a
recent population based study showing a reduction in ER/PR
negative breast tumors in women treated with lipophilic statins
such as Simvastatin [49]. The basal subtype is characterized by an
ER/PR negative status suggesting that the reduction in this form
of cancer could indeed reflect a selective effect on the basal
subtype. Given this connection, and the fact that Simvastatin is an
approved drug with known toxicity profiles, we suggest that a
clinical study is warranted to evaluate the activity of Simvastatin in
women with the basal subtype of disease.
Supporting Information
Figure S1 Classification of cultured breast cancer cell lines. A.
Unsupervised classification using the basal-luminal classifier genes.
For the classifier, we used gene sets (305 probes) described in the
original study (1). Expression values of RMA (robust multichip
average) normalized data for these probes were gene-centered and
normalized. We then performed hierarchical clustering by average
linkage. Expression levels of selected genes are shown in a
heatmap (high=red and low=blue). B. Supervised classification
using a binary regression method. The predicted probability of the
19 breast cancer cells for the similarity to basal (blue) or luminal
(red) is shown in a heatmap and sorted according to the similarity.
Note that the HCC1468 cell line, which was classified as a luminal
subtype in the original work (1), was predicted to belong to the
basal subtype by both the unsupervised and supervised methods.
We therefore have designated HCC1468 cells as basal phenotype
for this study. Reference 1. Neve RM, Chin K, Fridlyand J, et al.
A collection of breast cancer cell lines for the study of functionally
distinct cancer subtypes. Cancer Cell 2006; 10: 515–27.
Found at: doi:10.1371/journal.pone.0006772.s001 (10.20 MB
EPS)
Figure S2 Influence of empirical parameters used for prediction
on correlation with compounds. Pearson correlation analysis of the
RAS prediction with Hypothemycin sensitivity (A) and that of the
PI3K prediction with LY294002 sensitivity (B). We altered the
number of genes to prioritize (left panels) or the number of
Drug Discovery by Genomics
PLoS ONE | www.plosone.org 8 August 2009 | Volume 4 | Issue 8 | e6772metagenes (right panels) and predicted the status of the phenotype
of the NCI-60 cell lines. We correlated the predicted probability
with sensitivity data and show the correlation coefficient with the
altered parameters. An arrow indicates the parameter used in this
study.
Found at: doi:10.1371/journal.pone.0006772.s002 (6.27 MB EPS)
Table S1 Detailed conditions for generation of cancer relevant
signatures. The parameters used in this study are shown.
Found at: doi:10.1371/journal.pone.0006772.s003 (0.03 MB
DOC)
Table S2 Compounds correlated with basal subtype in NCI-60
data. 85 compounds with chemical names (or equivalents), which
are correlated with the basal subtype, are shown in this table.
Clinically used drugs are labeled by bold font. NSC numbers are
IDs for each compound in NCI-60 data. Abbreviations: R;
correlation coefficient and FDR; false discovery rate.
Found at: doi:10.1371/journal.pone.0006772.s004 (0.14 MB
DOC)
Table S3 GI50s of Simvastatin, Peplomycin and Tamoxifen in
our breast cancer cell lines. GI50 values of Simvastatin,
Peplomycin and Tamoxifen for our 19 breast cancer cell lines
are shown with standard error of the mean. Microarray-based
subtype classification is also indicated in the table.
Found at: doi:10.1371/journal.pone.0006772.s005 (0.04 MB
DOC)
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